<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681638</url>
  </required_header>
  <id_info>
    <org_study_id>CNTR-2020-001</org_study_id>
    <secondary_id>CDMRP-DM190167</secondary_id>
    <nct_id>NCT04681638</nct_id>
  </id_info>
  <brief_title>Plasma Resuscitation Without Lung Injury</brief_title>
  <acronym>PROPOLIS</acronym>
  <official_title>Plasma Resuscitation withOut Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coalition for National Trauma Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cerus Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Coalition for National Trauma Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment of patients with major burns requires resuscitation with massive amounts of&#xD;
      fluid, typically a type of salt water that is given by vein. This frequently results in&#xD;
      injury to vital organs, especially the lungs and kidneys, and even in death. In this study,&#xD;
      the investigators propose to use plasma, a specially prepared blood product made from the&#xD;
      liquid part of blood, that has undergone special treatment to reduce the risk of disease&#xD;
      transmission. The aims include 1) reduce the amount of fluid given during the first 24 hours&#xD;
      after a burn 2) reduce the incidence of lung injury and other complications related to the&#xD;
      administration of funds and 3) determine if the blood product has any effect on inflammation.&#xD;
      An overall decrease the amount of fluids that burn patients receive should decrease the&#xD;
      potential for lung injury, decrease days in the hospital, and improve survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open-label, phase IV, multicenter, randomized controlled prospective clinical trial in patients with burns. The study model is parallel (between-patient). The intervention to be tested is Pathogen-Reduced Plasma for burn shock resuscitation vs. standard-of-care resuscitation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The total volume of all resuscitation fluids delivered between hours 0-24 postern, in ml/kg.</measure>
    <time_frame>24 hours</time_frame>
    <description>The total volume of all resuscitation fluids delivered between hours 0-24 postburn, in ml/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total resuscitation volume in ml/kg</measure>
    <time_frame>48 hours</time_frame>
    <description>The total volume of all resuscitation fluids delivered between hours 0-48 postburn, in ml/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 24 hour resuscitation volume in ml/kg/TBSA</measure>
    <time_frame>24 hours</time_frame>
    <description>The total volume of all resuscitation fluids delivered between hours 0-24 postburn, in ml/kg/TBSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total 48 hour resuscitation volume in ml/kg/TBSA</measure>
    <time_frame>48 hours</time_frame>
    <description>The total volume of all resuscitation fluids delivered between hours 0-48 postburn, in ml/kg/TBSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic instability</measure>
    <time_frame>48 hours</time_frame>
    <description>Severity and duration of hemodynamic instability during hours 0-48 postburn (norepinephrine equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic acidosis</measure>
    <time_frame>48 hours</time_frame>
    <description>Severity and duration of metabolic acidosis (arterial lactate levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;rescue&quot; (a)</measure>
    <time_frame>48 hours</time_frame>
    <description>Initiation of extracorporeal therapy (continuous renal replacement therapy or therapeutic plasma exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;rescue&quot; (b)</measure>
    <time_frame>48 hours</time_frame>
    <description>Infusion of high-dose ascorbic acid (66 mg/kg/hr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of &quot;rescue&quot; (c)</measure>
    <time_frame>24 hours</time_frame>
    <description>Initiation of a continuous infusion of albumin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Respiratory Distress Syndrome</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of Acute Respiratory Distress Syndrome using Berlin Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>Ventilator free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit days</measure>
    <time_frame>28 days</time_frame>
    <description>Intensive Care Unit free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multi-Organ Failure Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Sequential Organ Failure Assessment scores. Minimum score 1, maximum score 4. The higher the score the worse the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion-Related Acute Lung Injury</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of Transfusion-Related Acute Lung Injury, Type I or II.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic events</measure>
    <time_frame>7 days</time_frame>
    <description>Incidence of venous thrombosis-embolic events (deep vein thrombosis or pulmonary embolism)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>throughout study completion, an average of 1 year</time_frame>
    <description>In hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Patient reported outcomes using the Patient Reported Outcomes Measurement Information System, Global 10. This scale10-item patient-reported questionnaire in which the response options are presented as 5-point (as well as a single 11-point) rating scales. The results of the questions are used to calculate two summary scores: a Global Physical Health Score and a Global Mental Health score. Higher scores equal a healthier patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Syndecan-1 levels</measure>
    <time_frame>48 hours</time_frame>
    <description>Syndecan-1 level in ng/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>48 hours</time_frame>
    <description>Cytokines</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pathogen-Reduced Plasma resuscitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crystalloid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standardized crystalloid resuscitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pathogen-Reduced Plasma</intervention_name>
    <description>The treatment group will receive an additional infusion of Pathogen-Reduced Plasma based on the formula, hourly rate, mL/hr = (1 mL*kg*TBSA)/24 hr. This infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.</description>
    <arm_group_label>Plasma</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crystalloid Solutions</intervention_name>
    <description>The control group will receive an additional infusion of LR based on the formula: hourly rate, mL/hr = (1mL*kg*TBSA)/24 hr. this infusion will not be titrated. It will be discontinued at the end of the 24th postburn hour.</description>
    <arm_group_label>Crystalloid</arm_group_label>
    <other_name>LR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Weight &gt; 40 kg&#xD;
&#xD;
          -  Initial assessment of thermal injury size ≥ 20% TBSA&#xD;
&#xD;
          -  Admitted to the burn center and enroll able within 8 hours of injury&#xD;
&#xD;
          -  Expected to receive intravenous resuscitation fluids for at least 24 hours after&#xD;
             injury&#xD;
&#xD;
          -  Expected to live &gt; 24 hours after injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemical injury&#xD;
&#xD;
          -  Deep electric injury&#xD;
&#xD;
          -  Associated non-thermal injuries with estimated Injury Severity Score &gt; 25&#xD;
&#xD;
          -  Inability to obtain informed consent&#xD;
&#xD;
          -  Decision not to treat due to injury severity or other factors&#xD;
&#xD;
          -  Patient age &gt; 65 years or &lt; 18 years&#xD;
&#xD;
          -  Presence of anoxic brain injury that is not expected to result in complete recover&#xD;
&#xD;
          -  Patent already receiving plasma infusion, or judged to be likely to require plasma&#xD;
             infusion&#xD;
&#xD;
          -  Patent already receiving &quot;rescue procedures&quot; (albumin infusion, CRRT, TPE, or&#xD;
             high-dose ascorbic acid)&#xD;
&#xD;
          -  Existence of pre-morbid conditions: Congestive heart failure (NYHA Class IV);&#xD;
             End-stage kidney disease (dialysis patient); Cirrhosis of the liver; Oxygen-dependent&#xD;
             chronic obstructive pulmonary disease; Malignancy currently under treatment; Previous&#xD;
             bilateral lower extremity amputations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Cancio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.S. Army Burn Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Phillips, MBA</last_name>
    <phone>210-884-3410</phone>
    <email>monica@nattrauma.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Price, PhD</last_name>
    <phone>210-455-8038</phone>
    <email>michelle@nattrauma.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Burn Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shannon Stephens</last_name>
      <phone>205-934-5890</phone>
      <email>swstephens@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jan Jensen, MBBS, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Blood Center</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tiffany Head</last_name>
      <phone>958-340-2341</phone>
      <email>tpoirrier@thebloodcenter.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosemary Kozar, MD</last_name>
      <phone>410-328-3495</phone>
      <email>rkozar@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Folliard, BSN</last_name>
      <phone>615-936-2876</phone>
      <email>sarah.folliard@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Robel Beyene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Nunez, PhD</last_name>
      <phone>214-648-0235</phone>
      <email>juna.nunez2@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin Levi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.S. Army Burn Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234-6315</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elsa Coates, BSN</last_name>
      <phone>210-916-0990</phone>
      <email>elsa.c.coates.civ@mail.mil</email>
    </contact>
    <investigator>
      <last_name>James Bynum, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leopoldo Cancio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch Shriners Burns Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Wolf, MD</last_name>
      <phone>409-770-6607</phone>
      <email>swolf@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Wolf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-2499</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Eschelbach, BSN</last_name>
      <phone>206-774-3587</phone>
      <email>eschee13@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Dagmar Amtmann, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barclay Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will become available one year after initial results publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

